Details of the Drug Reposition

General Information of This Drug (ID: DMH5YQ3)

Drug Name
Sugemalimab   DMH5YQ3
Drug Type
Monoclonal antibody

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Non-small-cell lung cancer DISI0V1B 2C25 Approved [1]
------------------------------------------------------------------------------------
1 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Extranodal NK/T-cell Lymphoma DIS72GCL 2A90.6 Phase 3 [2]
------------------------------------------------------------------------------------

References

1 Sugemalimab: First Approval. Drugs. 2022 Apr;82(5):593-599.
2 ClinicalTrials.gov (NCT05700448) A Phase III, Randomized, Double-Blind, Multicenter Study of Sugemalimab (CS1001) Plus PGemOx Regimen Versus Placebo Plus PGemOx for Subjects With Relapsed or Refractory Extranodal NK/T-Cell Lymphoma (R/R ENKTL). U.S.National Institutes of Health.